TipRanks
Advertisement
Advertisement
Regulatory Overhang and Funding Needs Keep Aardvark’s ARD-101 Outlook Balanced, Justifying Neutral Rating
PremiumRatingsRegulatory Overhang and Funding Needs Keep Aardvark’s ARD-101 Outlook Balanced, Justifying Neutral Rating
2M ago
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges
Premium
Company Announcements
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges
2M ago
Ram Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds
Premium
Ratings
Ram Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds
3M ago
Aardvark Therapeutics Inc trading halted, volatility trading pause
PremiumThe FlyAardvark Therapeutics Inc trading halted, volatility trading pause
5M ago
Aardvark Therapeutics Inc trading resumes
Premium
The Fly
Aardvark Therapeutics Inc trading resumes
5M ago
Aardvark Therapeutics downgraded to Neutral from Buy at BTIG
Premium
The Fly
Aardvark Therapeutics downgraded to Neutral from Buy at BTIG
5M ago
Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)
PremiumThe FlyAardvark Therapeutics reports Q1 EPS (99c), consensus (91c)
5M ago
Options Volatility and Implied Earnings Moves Today, April 06, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves Today, April 06, 2026
6M ago
Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―